Investigational drug · Phase 2
XPro1595
Also called: INB03, XPro, XENP1595, DN-TNF
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Alzheimer Disease, Dementia, Brain Diseases.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
5
Any phase or sponsor naming "XPro1595"
First trial start
2022
Feb 28, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "XPro1595", any sponsor or status.
Conditions studied
As listed on its trial records.
- Alzheimer Disease
- Dementia
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Tauopathies
- Neurodegenerative Diseases
- Neurocognitive Disorders
- Mental Disorders
- Mild Cognitive Impairment
Approved drugs for the same conditions: Alzheimer's disease · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "XPro1595" as an intervention, largest first.
- A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of InflammationPivotal-lookingCompleted
Inmune Bio, Inc.Industry
NCT05318976 · 207 participants · Start Feb 28, 2022 · Primary completion May 12, 2025
Drug: XPro1595; Placebo · For: Alzheimer Disease; Dementia; Brain Diseases and 7 more
Sites: Darlinghurst, Australia; Macquarie Park, Australia; Adelaide, Australia · 41 sites in all
- INB03 for the Treatment of Pulmonary Complications From COVID-19Pivotal-lookingTerminated
Inmune Bio, Inc.Industry
NCT04370236 · 79 participants · Start Oct 21, 2020 · Primary completion Oct 13, 2021
Drug: INB03; Placebo · For: COVID-19
Sites: Jonesboro, Arkansas; Louisville, Kentucky; Kosciusko, Mississippi · 9 sites in all
Inmune Bio, Inc.Industry
NCT03943264 · 20 participants · Start Nov 20, 2019 · Primary completion Jun 30, 2021
Drug: XPro1595 · For: Alzheimer Disease
Sites: Macquarie Park, Australia; Brisbane, Australia; Woodville, Australia · 5 sites in all
Inmune Bio, Inc.Industry
NCT05522387 · 11 participants · Start Feb 21, 2023 · Primary completion Jun 5, 2024
Drug: XPro1595 · For: Alzheimer Disease; Dementia; Brain Diseases and 6 more
Sites: Macquarie Park, Australia; Carlton, Australia; Ivanhoe, Australia · 4 sites in all
Inmune Bio, Inc.Industry
NCT05321498 · 0 participants · Start Jun 2023 · Primary completion Oct 26, 2023
Drug: XPro1595; Placebo · For: Mild Cognitive Impairment (MCI); Alzheimer Disease; Dementia and 6 more
Newest research
PubMed records naming it or its code names, newest first.
- [Resistance to cyclic fatigue of Protaper Gold, 2Shape and X-Pro Gold Files with different endontical motors].
Matumay Santos FDP, García-Rupaya CR · Rev Cient Odontol (Lima) 2026
- Inhibition of Soluble TNF Mitigates Traumatic Brain Injury as a Risk Factor for the Development of Amyloidogenic Proteins and Functional Deficits in 3xTg-AD Mice.
Poffenberger CN, Taylor MM, Larson K, et al. · J Neurotrauma 2026
- [Research progress on multidimensional biological functions and targeted intervention strategies of dipeptidyl peptidase 4].
Tao X, Gu R, Tao F, et al. · Sheng Wu Gong Cheng Xue Bao 2026
- Selective Inhibition of Tumor Necrosis Factor for Attenuating Alzheimer's Disease: Strategies Targeting Neuroinflammation.
Udaiyappan JP, Balakrishnan R, Tamilarasan MM, et al. · Inflammation 2026
- Stability and Efficacy of Fungicides Registered for Organic and Commercial Wheat Production in Hungary Against Fusarium Head Blight-A Comprehensive Methodology to Enhance Food Safety.
Meszlényi T, Ács K, Berényi A, et al. · Toxins (Basel) 2026
- Xpro®1595 alleviates neuropathic pain by targeting spinal dorsal horn ADAM17-mediated inflammation.
Li L, Su Y, Sun LL, et al. · Neurobiol Pain 2026
Also in development for Alzheimer Disease
- KarX-ECBMS-986519, Xanomeline Enteric-coatedPhase 39 trials
Bristol Myers Squibb · Alzheimer Disease, Alzheimer's Disease, Irritability Associated With Autism Spectrum Disorder
- ITI-1284JNJ-99245354Phase 36 trials
Intra-Cellular Therapies, Inc. · Generalized Anxiety Disorder, Agitation Associated With Alzheimer's Dementia, Psychotic Disorders
- AXS-05dextromethorphan-bupropionPhase 33 trials
Axsome Therapeutics, Inc. · Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Smoking Cessation
- MasitinibAB1010Phase 33 trials
AB Science · Amyotrophic Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS), Alzheimer Disease
- SPG302TazbentetolPhase 33 trials
Spinogenix · Alzheimer Disease, Schizophrenia, Amyotrophic Lateral Sclerosis
- Combined metabolic activatorsPhase 32 trials
ScandiBio Therapeutics AB · Alzheimer Disease, Gout Disease
- DMB-IINN: Latrepirdine, DimebonPhase 32 trials
Bigespas LTD · Alzheimer Type Dementia, Alzheimer Disease, Dementia of Alzheimer Type
- AR1001Phase 31 trial
AriBio Co., Ltd. · Alzheimer Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.